Paroli and Sirinian (Sapienza University of Rome) propose a "glial-cytokine-pain" framework: systemic inflammation in SARDs (RA, SLE, Sjögren's) feeds forward through peripheral cytokines (TNF-α, IL-6, IL-17), BBB compromise, microglial/astrocytic activation, and SFN-driven afferent injury, producing central sensitization and dysautonomia that persist even when synovitis is controlled .
Strongest evidentiary pillars in the paper: (1) TSPO-PET imaging showing glial activation in fibromyalgia and SLE cohorts ; (2) biopsy-confirmed SFN in ~49% of fibromyalgia patients across eight studies ; (3) passive transfer of IgG from fibromyalgia patients producing sensory hypersensitivity in mice ; (4) the vagal "inflammatory reflex" .
Critical caveats BGPT flags: The authors honestly concede the framework is "fragmentary" and a unifying model is lacking; the central sensitization→residual pain link in SARDs is explicitly framed as a hypothesis. Much support comes from murine arthritis/lupus models (e.g., collagen-induced arthritis, lupus microglial stripping) whose human translation is unproven, and TSPO-PET ligand specificity and SFN diagnostic heterogeneity (non-standardized IENFD criteria across small studies) remain unresolved. As a narrative review with no systematic search or quality appraisal, selection and citation bias cannot be excluded. The related RHD literature shows that retrospective, small-cohort rheumatology evidence frequently overstates confidence .
Bar lengths are BGPT's qualitative tiering of evidence class cited in the review—not measured quantities.
The review succeeds as an integrative, well-referenced (156 refs) roadmap that reframes residual pain/fatigue in SARDs as biologically grounded neuroimmune phenomena and pushes pain phenotyping (inflammatory vs neuropathic vs nociplastic) plus COMPASS-31/CSI screening into rheumatology. It does not yet prove causality; validating claims requires prospective human cohorts combining IENFD biopsy, TSPO-PET, QST, HRV, and outcome-linked biomarkers. Falsification would entail demonstrating central sensitization/autonomic dysfunction independent of, or symptom burden fully explained by, peripheral inflammation .
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.